AstraZeneca’s Cancer Drug Trial Disappoints, Sending Shares Lower

Photo of AstraZeneca’s Cancer Drug Trial Disappoints, Sending Shares Lower
Facebook
VKontakte
share_fav

The hotly anticipated treatment had been expected to be a crucial driver of growth for the company as it faces more competition from generic pharmaceuticals.

view The New York Times: Business
#inventions and patents
#drugs pharmaceuticals
#crestor drug
#astrazeneca plc